Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MITF | O75030 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876732 | 0.82 | MAOA (0.57) | MAOAALDH1A1MAPTPOLBKDM4E | |
| SCHEMBL4874202 | 0.80 | MAOA (0.51) | MAOAALDH1A1MAPT | |
| SCHEMBL31237670 | 0.76 | CASP3 (0.72) | CASP3ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4294197 | 0.76 | CASP3 (0.72) | CASP3ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9630631 | 0.76 | CASP3 (0.72) | CASP3ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9081388 | 0.75 | NPC1 (0.76) | CASP3ALDH1A1HTTSMN1; SMN2MITF | |
| SCHEMBL21409465 | 0.72 | MITF (0.51) | CASP3ALDH1A1HTTSMN1; SMN2MITF | |
| SCHEMBL11802189 | 0.72 | ALDH1A1 (0.67) | ALDH1A1HTTSMN1; SMN2MITFNPC1 | |
| SCHEMBL4869345 | 0.72 | CA12 (0.68) | CASP3MAOASMN1; SMN2NPC1RAB9A | |
| SCHEMBL24534239 | 0.72 | CASP3 (0.62) | CASP3ALDH1A1HTTSMN1; SMN2MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070963-A1 | Compositions and methods for promoting neural regeneration | Neuberger, Timothy | 2008-03-20 | — | — | US | disclosed |
| US-7271187-B2 | Compositions and methods for promoting tissue regeneration | Neuberger, Tim (US) | 2007-09-18 | — | — | US | disclosed |
| US-20020055530-A1 | Compositions and methods for promoting tissue regeneration | URI HERZBERG | 2002-05-09 | — | — | US | disclosed |
| WO-2001076592-A1 | COMPOSITIONS AND METHODS FOR PROMOTING NEURAL REGENERATION | ACORDA THERAPEUTICS, INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| US-4965284-A | IMMUNOMODULATORS | AMERICAN CYANAMID COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0342433-A2 | Substituted dibenzothiaphenes | AMERICAN CYANAMID COMPANY (US) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055530-A1 | Compositions and methods for promoting tissue regeneration | TST, DCX, GAP43 | CASP3 265/4885MAOA 2786/4885ALDH1A1 381/4885 |
| US-20080070963-A1 | Compositions and methods for promoting neural regeneration | GAP43, DCX, BDNF | CASP3 283/4885MAOA 2786/4885ALDH1A1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.